Answers are grounded in this paper and cite their sources.
Despite the introduction of strict hygienic precautions preventing infection spread of hepatitis C virus (HCV) in dialysis settings, this infection is still prevalent among dialysis patients due to procedures making the patients vulnerable to infection through blood contamination. Treatment of HCV infection in dialysis patients is also less successful than that in the non-uremic population due to contraindication of using ribavirin, a main drug, in the infected patients. In this review article we aim to investigate the feasibility of the current antiviral therapies in dialysis patients infected with HCV infection.
No takes yet. Share an insight, caveat, or question.
Ghamarchehreh et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: